Last Price$61.4(0.0%)
Market Cap$7,773.1M
LTM Gross margin
80.8%
5Y avg
79.0%
Biotechnology industry
median
69.2%
Stock quality & Intrinsic value
8/10
(0.1%) overvalued
Halozyme Therapeutics, Inc. Gross margin
Annual
Quarterly
LTM
Industry median
Company stand-alone
Crunching data... Almost there!
| Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 59.1% | 55.5% | 93.7% | 96.2% | 97.7% | 92.8% | 99.5% | 97.4% | 88.6% | 69.8% | 78.3% | 77.4% | 90.2% | 93.3% | 76.8% | 83.8% | 81.6% | 78.9% | 76.8% | 84.3% |
Overvalued or undervalued?
Check the intrinsic value for HALO
and see if it's the right time to invest.
Halozyme Therapeutics, Inc. (HALO) Gross margin comparison analysis
General
LTM Gross margin
OTHER METRICS
Company name
Revenue growth
EPS growth
Net Income margin
Halozyme Therapeutics, Inc.HALO
80.8%
22.4%
64.3%
43.7%
Median Peer Set
84.1%
14.8%
(19.3%)
7.5%
United Therapeutics CorporationUTHR
89.2%
23.6%
25.7%
41.5%
argenx SEARGX
86.8%
198.6%
(60.5%)
(24.1%)
Vertex Pharmaceuticals IncorporatedVRTX
86.1%
11.7%
N/A
(4.9%)
Alnylam Pharmaceuticals, Inc.ALNY
85.6%
23.0%
(38.6%)
(12.4%)
Regeneron Pharmaceuticals, Inc.REGN
84.5%
8.3%
10.4%
31.1%
BeiGene, Ltd.BGNE
83.7%
73.7%
467.1%
(35.9%)
BioNTech SEBNTX
80.3%
(77.4%)
(89.7%)
24.4%
BioMarin Pharmaceutical Inc.BMRN
78.6%
18.0%
139.3%
15.0%
Royalty Pharma plcRPRX
73.9%
(3.8%)
(43.7%)
37.9%
Summit Therapeutics Inc.SMMT
N/A
N/A
(68.7%)
N/A
HALO key stats
USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
| Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% growth | 0.1 0.0% | 1.0 671.8% | 3.8 287.0% | 8.8 130.7% | 13.7 56.0% | 13.6 (0.3%) | 56.1 311.7% | 42.3 (24.5%) | 54.8 29.5% | 75.3 37.5% | 135.1 79.3% | 146.7 8.6% | 316.6 115.8% | 151.9 (52.0%) | 196.0 29.1% | 267.6 36.5% | 443.3 65.7% | 660.1 48.9% | 829.3 25.6% | 1,015.3 22.4% |
| Cost of Goods Sold (COGS) | 0.1 | 0.4 | 0.2 | 0.3 | 0.3 | 1.0 | 0.3 | 1.1 | 6.2 | 22.7 | 29.2 | 33.2 | 31.2 | 10.1 | 45.5 | 43.4 | 81.4 | 139.3 | 192.4 | 159.4 |
% margin | 0.1 59.1% | 0.5 55.5% | 3.6 93.7% | 8.4 96.2% | 13.4 97.7% | 12.6 92.8% | 55.8 99.5% | 41.2 97.4% | 48.6 88.6% | 52.6 69.8% | 105.8 78.3% | 113.5 77.4% | 285.5 90.2% | 141.7 93.3% | 150.4 76.8% | 224.2 83.8% | 361.9 81.6% | 520.8 78.9% | 636.9 76.8% | 855.9 84.3% |
| Operating Expenses | 13.6 | 16.1 | 31.7 | 58.9 | 71.8 | 66.9 | 75.7 | 94.9 | 129.0 | 115.6 | 133.3 | 196.7 | 204.5 | 211.1 | 218.1 | 80.0 | 86.0 | 253.3 | 299.3 | 304.4 |
| Research & Development Expenses (R&D) | 10.2 | 9.2 | 20.6 | 44.2 | 56.6 | 51.8 | 57.6 | 70.0 | 96.6 | 79.7 | 93.2 | 150.8 | 150.6 | 150.3 | 140.8 | 34.2 | 35.7 | 66.6 | 76.4 | 79.0 |
| Selling, General & Administrative Expenses (SG&A) | 3.4 | 6.9 | 11.2 | 14.6 | 15.2 | 15.1 | 18.1 | 24.8 | 32.3 | 35.9 | 40.0 | 45.9 | 53.8 | 60.8 | 77.3 | 45.7 | 50.3 | 143.5 | 149.2 | 154.3 |
% margin | (13.6) (10,660.7%) | (15.6) (1,587.3%) | (28.2) (740.9%) | (50.4) (575.5%) | (58.5) (427.6%) | (54.3) (398.2%) | (19.8) (35.4%) | (53.6) (126.7%) | (80.4) (146.8%) | (63.0) (83.7%) | (27.5) (20.3%) | (83.2) (56.7%) | 81.0 25.6% | (69.3) (45.7%) | (67.6) (34.5%) | 144.3 53.9% | 275.9 62.2% | 267.5 40.5% | 337.6 40.7% | 551.5 54.3% |
| Interest Income | 0.0 | 0.0 | 0.0 | 1.7 | 0.1 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 7.1 | 15.0 | 6.4 | 15.9 | 0.0 | 0.0 |
| Interest Expense | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 3.3 | 5.6 | 5.2 | 20.0 | 22.0 | 18.0 | 11.6 | 20.4 | 7.5 | 16.9 | 18.8 | 18.1 |
| Pre-tax Income | (13.3) | 0.0 | 0.0 | (48.7) | (58.4) | (53.2) | (19,769.9) | (53.6) | (83.5) | (68.4) | (32.2) | (101.9) | 61.6 | (79.8) | (72.3) | 129.3 | 248.5 | 248.9 | 348.3 | 557.1 |
% effective tax rate | (0.3) 2.2% | (0.8) 0.0% | (4.3) 0.0% | (0.1) 0.1% | 0.0 0.0% | (1.0) 1.9% | (1.2) 0.0% | (1.1) 2.1% | 2.0 (2.5%) | 3.8 (5.6%) | 3.5 (10.9%) | 1.2 (1.1%) | (1.4) (2.2%) | 0.5 (0.7%) | (0.0) 0.0% | 0.2 0.2% | (154.2) (62.0%) | 46.8 18.8% | 66.7 19.2% | 113.0 20.3% |
% margin | (13.3) (10,435.9%) | (14.8) (1,502.6%) | (23.9) (628.9%) | (48.7) (555.2%) | (58.4) (426.9%) | (53.2) (390.8%) | (19.8) (35.2%) | (53.6) (126.5%) | (83.5) (152.3%) | (68.4) (90.8%) | (32.2) (23.9%) | (103.0) (70.2%) | 63.0 19.9% | (80.3) (52.9%) | (72.2) (36.9%) | 129.1 48.2% | 402.7 90.8% | 202.1 30.6% | 281.6 34.0% | 444.1 43.7% |
| EPS | (0.26) | (0.24) | (0.32) | (0.61) | (0.67) | (0.56) | (0.19) | (0.48) | (0.74) | (0.56) | (0.25) | (0.81) | 0.46 | (0.56) | (0.50) | 0.95 | 2.86 | 1.48 | 2.13 | 3.50 |
| Diluted EPS | (0.26) | (0.24) | (0.32) | (0.61) | (0.67) | (0.56) | (0.19) | (0.48) | (0.74) | (0.56) | (0.25) | (0.81) | 0.45 | (0.56) | (0.50) | 0.91 | 2.74 | 1.44 | 2.10 | 3.43 |
% margin | (13.4) (10,498.5%) | (14.5) (1,477.8%) | (28.2) (740.9%) | (49.4) (563.5%) | (56.9) (416.3%) | (52.7) (387.2%) | (18.7) (33.3%) | (52.5) (124.0%) | (79.0) (144.1%) | (61.0) (81.0%) | (25.4) (18.8%) | (79.5) (54.2%) | 83.2 26.3% | (69.3) (45.7%) | (56.6) (28.9%) | 153.0 57.2% | 259.0 58.4% | 315.5 47.8% | 451.9 54.5% | 656.5 64.7% |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
FAQ
1) What is Halozyme Therapeutics, Inc.'s Gross margin?
As of today, Microsoft Corp's last 12-month Gross margin is 80.8%, based on the financial report for Dec 31, 2024 (Q4’2024). The average annual Gross margin for Halozyme Therapeutics, Inc. have been 79.2% over the past three years, and 82.9% over the past five years.
2) Is Halozyme Therapeutics, Inc.'s Gross margin Good?
As of today, Halozyme Therapeutics, Inc.'s Gross margin is 80.8%, which is higher than industry median of 69.2%. It indicates that Halozyme Therapeutics, Inc.'s Gross margin is Good.